The lipid-based nanostructured drug carriers designed for the Docetaxel delivery

Cancer is one of the leading causes of mortality worldwide, accounting for one in six deaths. In Brazil, non-melanoma skin cancer is the most prevalent, responsible for approximately 185,000 new cases each year. The main antineoplastic agents, such as docetaxel (DTX) have limitations such as low water solubility, tissue toxicity and rapid degradation. Such challenges can be overcome with the use of nanocarriers, as in the case of nanostructured lipid carriers (NLC). This compound is a promising contribution by nanotechnology in pharmaceutical sciences. The applicability of NLC in drug delivery allows increasing the bioavailability of pharmacological active compounds [3,4]. We developed a nanostructured hybrid system composed of NLC incorporating docetaxel (DTX, 0.5%) adsorbed on a biopolymeric matrix of xanthan-chitosan gum (3:1%). Through this formulation, an innovative drug delivery system for the treatment of skin cancer is proposed to release DTX. Our objective in this proposal is to study the structural organization of lipid-based drug delivery systems: NLC composed of Myristyl Myristate (SL) and Miglyol 812 (LL) in two different concentrations containing DTX and the surfactant Pluronic F58, in addition to Copaiba Oil. To this end, we are submitting this proposal to measure our samples at SANS2d beamtime, which will be very important for characterizing our drug delivery system.